Review Article

Tryptase plays a role in solid tumor angiogenesis and cell proliferation

Anisha Mathew¹, Manisha Naithani¹*, Amit Sehrawat², Deepak Sundriyal², Pulturu Venkata¹ Shilpa, Uttam Kumar Nath²

¹Department of Biochemistry, All India Institute Medical Sciences Rishikesh, Rishikesh, Uttarakhand, India
²Department of Medical Oncology Hematology, All India Institute Medical Sciences Rishikesh, Rishikesh, Uttarakhand, India

Received: 08 August 2020
Accepted: 14 August 2020

*Correspondence:
Dr. Manisha Naithani,
E-mail: naithanimanisha@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT
Tryptase, a serine protease released during mast cell degranulation has been associated with anaphylactic reactions and inflammations. In recent studies on solid tumor proliferation, it has been seen that tryptase has a role in tumor angiogenesis and tumor cell proliferation. This also makes tryptase a potential therapeutic target. Many anti-tryptase agents have shown to decrease tumor angiogenesis and proliferation. Authors have thus reviewed various articles which have done extensive studies on the role of tryptase as an important factor in tumor proliferation and angiogenesis.

Keywords: Solid tumor, Tryptase, Tumor angiogenesis

INTRODUCTION
Tryptase is a 134 kDa serine protease enzyme, deriving its name from its trypsin-like activity of cleaving peptides or protein substrates. In theory, tryptase cleaves a fragile or amide bond at the carboxyl end of lysine or arginine residues. Tryptase has been commonly expressed by mast cells and seen minorly in immature basophils and leukemic cells of patients suffering from various myeloid and leukemic disorders. The normal levels of tryptase have been recorded as 5-11 ng/dl.¹-⁴

Tryptase is encoded on the short arm of chromosome 16, specifically expressed by mast cells (MC’s) which are of subtypes, α, β, γ and δ. Each type encodes a leader chain of 30 AA and catalytic proteins of 245 AA. Tryptase was originally identified to be a marker of anaphylaxis and inflammation, as its serum levels rise alongside histamine during an attack of anaphylaxis. This is because of increased mast cell production during anaphylactic shock. Tryptase is also seen increased in people with a history of asthma, allergic rhinitis, etc., due to the massive involvement of mast cell in these conditions.¹,⁵-⁷ Further studies also revealed that mast cell tryptase plays a role in the proliferation and angiogenesis of solid tumors.

TRYP TASE INCREASES TUMOR PROLIFERATION AND ANGIOGENESIS

Tumor microenvironment includes not only the malignant cells but also a milieu of the immune cells and increased vasculature and lymphatic systems. These include T and B lymphocytes, tumor-associated macrophages, MC’s, endothelial cells, etc. These factors increase signal transduction pathways such as mitogen-activated protein kinase kinase kinase (MEKK) pathway and also induce increased expression of angiogenic factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), etc. All these increase tumor cell proliferations and angiogenesis (Table 1).⁵

Tryptase is released from MC’s when the stem factor binds to tyrosine kinase c-kit R on MC surface, leading to
degranulation of cells and release of tryptase. Tryptase acts as an agonist of G-protein coupled receptor superfamily, protease-activated receptor-2 (PAR-2) of epithelial and endothelial cells. Tryptase activates PAR-2. This in turn results in G-protein coupled transduction resulting in phosphatidylinositol hydrolysis and elevation of Ca2+ in tumor cells. Increased calcium levels activate G-protein coupled signal transduction and phosphorylated extracellular signal-related kinase (ERK) and mitogen-activated protein kinase (MEKK/MAPK). Increased calcium levels also activate increased secretion of prostaglandin E2 (PGE2) and cyclo-oxygenase-2 (COX-2). Sodium hydrogen antiporter-3 regulator-1 (NHERF-1), present in various normal and tumor cells, is activated through Erzin/protein kinase A mediation, and regulates many transmembrane receptors, transporters and other proteins which play a role in cancer cell proliferation (Table 1).\textsuperscript{1,7,9}

VEGF expression on endothelial and intestinal cell surfaces is also increased by tryptase activated PAR-2, thus playing a role in tumor proliferation, growth, and angiogenesis. This theory was tested out in human colon carcinoma cell lines which were reported by Ilaria Marech et al. Tryptase can be translated as therapeutic targets in cancer due to its role as a tumor angiogenesis factor. Release of tryptase from mast cells can be inhibited with help of tryptase inhibitors such as gabexate mesylate and nafamostat mesylate in combination with tyrosine kinase inhibitors imatinib/ masitinib which hinder mast cell activation and c-KIT2 induced degranulation (Table 1).\textsuperscript{1,7,9,10}

### Table 1: Studies on the role of tryptase in tumor angiogenesis in cancer.

| Study | Methodology | Result | Conclusion |
|-------|-------------|--------|------------|
| Kankkunen et al\textsuperscript{15} | Immunohistochemistry and Microscopy of Mast cells -Polyclonal anti-tryptase antibody (Rabbit) -MAbs- anti-chymase antibody B7 (Mouse) | In benign lesion, tryptase activity was equal to that of chymase -In malignant breast cancer tryptase activity was higher than chymase | Mast cells showed higher tryptase activity than Chymase activity, especially in malignant breast tissues than in benign breast tissues. |
| Ribatti et al\textsuperscript{16} | Immunohistochemistry Antibodies used -MAbs against endothelial cell marker (CD31) (MAb 1A10) and tryptase | Tryptase +ve MCs increased with microvascular count especially in lymph nodes -Angiogenesis in SLN was contributed by tryptase mast cell | Tryptase is associated with increased microvascular count signifying its role with angiogenesis in tumor cell |
| Ranieri\textsuperscript{17} | Immunohistochemistry -Anti-CD34 and anti-tryptase Human-specific monoclonal antibodies | Tryptase +ve mast cells were increased around vascularized regions and was involved in tissue remodelling. -Tryptase indirectly induced tissue neovascularization by releasing angiogenic factors | Raised levels of tryptase +ve mast cell is associated with tumor cell neovascularization and tissue re-modelling |
| Xiang et al\textsuperscript{14} | Immunohistochemistry assay -IgG1x monoclonal antibody B12; acts on epitope of Tryptase Cell culture: -MDA-MB231 -Migration assays and in vitro cell invasion Gelatin zymography to evaluate MMP-2 expression | Grade 3 breast cancer specimens had higher tryptase expression when compared with grade 1 and 2 -no significant in cell proliferation despite tryptase treatment -Tryptase increased invasion of breast cancer cells -Groups having increased Tryptase levels also had increased cell invasion | Grade 3 breast cancer has higher tryptase expression and this was associated with cellular invasions, however there was no significant role of tryptase in cell proliferation |
| Marech et al\textsuperscript{12} | Immunohistochemistry -Specific monoclonal antibodies anti-tryptase and anti-CD34 staining in adjacent sections Morphometrical assay -(Quantiimet500 Leica, Wetzlar, Germany) image analysis system was utilized | Tryptase burden was from mast cell degranulation -Tryptase stimulates formation of vascular tubes in vitro and in vivo experimental models. -Tryptase acting as an agonist of PAR-2, stimulates release of latent angiogenic factors | Tryptase as a PAR-2 agonist promotes tumor angiogenesis via stimulation and release of other angiogenic factors |
| Marech et al\textsuperscript{13} | Immunohistochemistry assay -Human specific MAbs (anti-CD34) -Rabbit polyclonal antibodies to e-KitR (ANTI-CD 117)) | In vitro, tryptase inhibitors suppressed ECs proliferation, suggesting proliferation is activated by tryptase -MCs-e-KitR and tryptase promotes angiogenesis in breast cancer | With the use of tryptase inhibitors, it established that mast cell tryptase and Mast Cell-e-KitR stimulates angiogenesis |

Continued.
| Study          | Methodology                                                                 | Result                                                                                                                                                                                                 | Conclusion                                                                                     |
|---------------|------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Qian et al 11 | Method: Cell culture EGM  
- In vitro wound-healing assay western blot electrophoresis  
- culture and identification of EPCs -Proliferation, migration, and assay of EPCs (lumen formation). RT-qPCR and semi-quantitative  
- Primers used: PAR-2 forward and reverse, VEGFR-2 forward and reverse, GAPDH as control | - Tryptase inhibited EPC migration and tube formation which was reversed by both tryptase inhibitor (APC366) and PAR-2 inhibitor (SAM 11)  
- Significantly increase in VEGFR-2 mRNA level in EPCs when treated with tryptase or a PAR-2 agonist  
- Tryptase may have direct role in EPC activation and migration through PAR-2/ERK signalling pathways | Tryptase activated PAR-2 receptors increased VEGFR-2 expression, playing a direct role in EPC activation and migration |
| Strouch et al 18 | Adenocarcinoma cell lines PANC-1 and AsPC1  
- Mast cell migration assay  
- Proliferation and invasion assay  
- Immunohistochemistry  
- Mouse based anti-human tryptase antibody (primary)  
- Dako anti-mouse IgG antibody (secondary)  
- Serum tryptase activity (mast cell degranulation assay) by quantitative spectrophotometric  
- Cell culture line: Human pancreatic ductal cell line | - Increased mast cell infiltration was statistically significant in the stroma of pancreatic cancer tissue especially when compared to adjacent normal pancreatic tissue and benign pancreatic tissue  
- In 36 serum samples of adenocarcinoma patients there was elevated serum tryptase activity  
- Mast cell migration orchestrated by tryptase activity | Significant mast cell infiltration in tumor pancreatic cells which was associated with elevated tryptase and increased mast cell migration |
| Guo et al 19 | IHC assay, ELISA assay  
- Serum Mast Cell Tryptase (MCT) level  
- qPCR  
- ANGPT1, TIE2, VEGF and PDGF mRNA expression  
- Cell culture- proliferation and tube formation  
- HUVEC cells and PANc-1 cell line  
- Western blotting nude mouse model -tumor formation assay | - In pancreatic cancer patients, serum tryptase was significantly correlated with higher microvascular density  
- Nafamostat, an MCT inhibitor could partly reverse the proliferative effect of tryptase  
- Promotion of endothelial cell growth and activate vascularization of tumor cells by Mast cell tryptase | In pancreatic cancer cell lines, tryptase promotes endothelial cell growth and activate tumor vascularisation |
| Ammendola et al 20 | Immunohistochemistry  
- Incubated with MAb1 anti-CD31  
- Using biotinylated secondary antibody, bound antibody was visualized, avidin-biotin Morphometrical assay | - In areas recognized as hot angiogenic beds, mast cells were identified in huge number  
- Increased angiogenesis associated with increased count of c-Kit+ MCs and MCD-T  
- c-Kit-R activation released Tryptase following degranulated MCs  
- Novel surrogate angiogenic markers in pancreatic cancer: c-Kit+ MCs and MCD-T | Tryptase release mediated by c-Kit+ activated degranulation of Mast Cells is a factor of increased tumor angiogenesis and can be used as a novel surrogate marker of pancreatic cancer |
| Ammendola et al 21 | Immunohistochemistry  
- Human-specific monoclonal antibodies against tryptase  
Morphometric Assay image For tryptase positive cells counted at a magnification of x40 | - MCT levels and number of metastatic lymph nodes showed positive correlation  
- Significant correlation among increased metastasis and tryptase positive mast cell density | MCT in primary tumor tissue considered as a marker of prognosis in gastrointestinal cancer patients before radical surgical treatment |

Continued.
TRYPTASE AS A MARKER OF ANGIOGENESIS IN SOLID TUMORS

Tryptase which is stored in MC granules as a tetramer complexed with heparin, has various roles such as activation of MCs, increasing blood vessel permeability, inflammatory cells infiltration, epithelial cell proliferation, and stimulation of IL-8 secretion. In preceding studies related to breast cancer, there was a significant association between increased tryptase and increased expression of VEGF-receptors and c-Kit receptors.11

Marech et al, demonstrated that serum tryptase levels in breast cancer correlated with MC’s and microvascular density. In their study, tryptase was found to induce in

| Study                  | Methodology                                                                 | Result                                                                 | Conclusion                                                                                       |
|------------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Malfettone et al22     | Immunohistochemical analysis for MCs -In the tissue stroma, appearance of tryptase (+) MCs -Sections incubated with polyclonal EBP50 antibody for NHERF1 (rabbit) -Antibodies against human MC-tryptase Immuno histo-fluorescence | -Low expression of PAR-2 in normal mucosa but highly expressed along tumor borders adjacent to vascular structures -Higher density of tryptase (+) MCs in tumors with distant metastases and poor differentiation grade -During wound healing and cancer, Tryptase involved in tissue remodelling by degrading selectively matrix proteins, synthesizing collagen | High density tryptase mast cells can be a marker of tissue remodelling and distant metastasis. Continued. |
| Ammendola et al23      | Fluoro-enzyme immunoassay -Serum tryptase levels Immunohistochemistry -4 mm-thick serial sections of formalin-fixed and paraffin-embedded tumour sample and -Tumour sections were incubated with an anti-tryptase antibody -Anti-CD34 antibody -Anti-VEGF antibody Morphometrical assay | -Tumour tissue MCT mean and adjacent normal mucosa MT mean showed significant difference (p=0.000). -Increased VEGF expression indicated by a strong cytoplasmic immunostaining in cancer tissue -Mast cells represent main source of serum tryptase in primary CRC tumour tissue | Raised tryptase levels in tumor tissues are important indicators of increased VEGF expression |
| Suzuki et al24         | Immunohistochemistry Tissue sections -Deparaffinized in xylene -Monoclonal antibodies (mouse) to recognize tryptase | -Significant independent predictor of unfavourable overall survival was high peritumoral mast cell infiltration -Tumor cell proliferation and angiogenesis promoted by tryptase which releases interleukin 6 and granulocyte macrophage colony-stimulating factor | Tryptase can be considered as an independent predictor of poor overall survival and tumor cell proliferation |
| Sammarco et al25       | Immunohistochemistry -Anti-tryptase -Anti-CD31 antibody -Secondary antibody (Biotinylated) Morphometrical assay Light microscopy integrated with an image analysis system | -Presence of tumors associated Macrophages (TAMs) and increased mast cell density positive for tryptase (MCDPT) together indicated as significant marker of gastric cancer angiogenesis | Coupled MCDPT and TAMs may be used as a surrogate biomarker of degree of gastric cancer angiogenesis |
| Endometrial cancer     | Immunohistochemistry -Micro vessel counts -Mast cell counts -Two murine monoclonal antibodies against endothelial cell marker (CD31) and tryptase | -Mast cells scattered in neoplastic tissue were found to be near or around blood capillaries -Tryptase positivity, increased Mast cells and presence of micro vessels makes tumor more invasive | Tryptase +ve mast cells are associated significantly with tumor invasion of greater than half of myometrium |

Mab: Monoclonal antibodies, MCs: Mast cells, SLN: Sentinel lymph nodes, MMP-2: Matrix metallopeptidase-2, CD: Cells of differentiation, ECs: Endothelial cells, EGM: Endothelial cell growth medium, EPCs: Endothelial progenitor cells, VEGFR: Vascular endothelial growth factor receptor, RT-qPCR: Reverse transcription quantitative polymerase chain reaction, PAR-2: Proteinase-activated receptor-2.
vitro endothelial cell proliferation in matrigel assay. This was supported by other studies in which it was observed that tryptase promoted endothelial progenitor cell (EPC) migration which was inhibited when tryptase inhibitors were used. Tryptase was found to promote endothelial tube formation and this significantly increased VEGF-2 RNA levels in EPC which was reversed when treated with tryptase and PAR-2 inhibitors. Mangia et al suggested that tryptase may be an initiator of carcinoma-associated fibroblasts.

As shown in Table 1, tryptase has a major role in promoting angiogenesis and tumor invasion in solid cancer which seems to increase with increasing stage of the disease. Further studies may be required to establish tryptase’s role as a marker for disease progression or severity. Treating the cell lines with tryptase inhibitors has shown to decrease the tumor neovascularization and migration of epithelial cells. Tryptase, thus, can serve as a possible new cancer therapy target.

Fig. 1: Tryptase inhibitors.

A similar finding was seen in studies involving pancreatic cancer. It was found that MC tryptase levels were higher in pancreatic cancer tissue. These levels also increased with increasing stage of the disease. Tryptase positive MC’s also had a correlation with expression of cKit-2 receptor which also significantly correlated with cell migration and angiogenesis. These receptors play an important role in activating VEGF-2 receptors which also would increase the tumor angiogenesis.

When mast cell density positive tryptase (MCDPT) levels were correlated with microvascular density in gastric, colo-rectal, and endometrial cancers, it was found that MCDPT was heavily populated near vessels in tumor tissue and were significantly in higher number in the tumor tissues than with normal adjacent tissue. Most of the tumors were of early-stage unlike study conducted by Xiang et al. It was demonstrated that with an increase in tryptase levels, there is activation of matrix metallo-proteinases (MMPs) which also increase angiogenesis in tumors.

As shown in Table 1, tryptase has a major role in promoting angiogenesis and tumor invasion in solid cancer which seems to increase with increasing stage of the disease. Further studies may be required to establish

TRYPSTATE AS A THERAPEUTIC TARGET IN SOLID TUMORS

As mentioned earlier, tryptase activates PAR-2 receptors on both endothelial cells and the tumor cells increasing gene transcription, cell proliferation, and angiogenesis. This increases tumor proliferation and increasing tumor growth. Many drugs have been studied as inhibitors of tryptase, some of which are Gabexate mesylate, Nafamostat mesylate, and Tranilast (Figure 1).

Gabexate mesylate, is a synthetic inhibitor of trypsin-like serine proteases. As tryptase has trypsin-like action, gabexate mesylate has shown selective inhibition of human tryptase producing inhibition of tumor invasion, metastasis, and angiogenesis. The activity of gabexate mesylate has been investigated in cases of colonic and pancreatic cancer cell lines. When used in combination with anti-epidermal growth factor receptor (EGFR) monoclonal antibody like cetuximab, gabexate mesylate has been found to downregulate the trypsin-like action of plasma proteases including tryptase and decreased proliferation of tumor cells.

Similar to gabexate mesylate, nafamostat mesylate inhibits a variety of serine proteases with trypsin-like activity including those involved in the coagulation process. Nafamostat mesylate has been suggested to be used as a therapeutic agent in conditions of increased tryptase levels like anaphylactic inflammations. Nafamostat mesylate action of tryptase inhibition mediates the role of nafamostat mesylate as an anticancer agent. With a mechanism of action similar to that of gabexate mesylate, previous studies showed that nafamostat mesylate antagonizes tryptase induced PAR-2 activity inhibiting invasion and proliferation of pancreatic cancer cells. Nafamostat mesylate anti-tumor activity has also been demonstrated by blockade of activation of nuclear factor kappa-B (NF-κB), thought to be induced by tryptase activity.

Tranilast which inhibits the action of tryptase in MC-mediated inflammations, has been approved as a treatment for various diseases like bronchial asthma, atopic dermatitis, and allergic conjunctivitis, in a few countries namely Japan and Korea. There were also reports of, both in vitro and in vivo, the role of tranilast as an inhibitor of VEGF-induced angiogenesis which is concomitant to its inhibitory role on mast cell degranulation. The most common mechanism of action of Tranilast is pathway reduction of MMP 9 and VEGF expression by downregulating TGF-β.
CONCLUSION

As tryptase has a proven role in tumor angiogenesis, it can be further studied as a marker of tumor progression and also as an anti-cancer therapy.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. Trivedi NN, Caughhey GH. Handbook of proteolytic enzymes. 3rd edition. Chapter: Human α-, β- and δ-trypase. Elsevier’s. 2013;2683-93.

2. Schwartz LB, Lewis RA, Seldin D, Austen KF. Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells. J Immunol. 1987;126(4):1290-4.

3. Immuno Cap Tryptase (Product Insert). Uppsala Sweden; 2007.

4. Human TPSABI/mast cell serum tryptase kit. User manual. Lifespan Biosciences. North America; 2009.

5. Foster B, Schwartz B, L, Devouassoux G, Metcalfe DD, Prusin C. Characterization of mast-cell tryptase- expressing peripheral blood cells as basophils. J Allergy Clin Immunol. 2002;109:287-93.

6. Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirhofer S, et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol. 2002;128:139-46.

7. Brahim SJ, Min HK, Fukuoka Y, Xia HZ, Schwatz BL. Expression of α-trypase and β-trypase by human basophils. J Allergy Clin Immunol. 2004;113(6):1086-92.

8. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591-6.

9. Kelta E, Ashall F, Abubeker A. Assessment of serum tryptase activity among acute and chronic myeloid leukemia patients visiting hematolog-oncology clinic at tikuranbessa specialized hospital and comparison with healthy controls. Cancer Res J. 2018;6(1):26-37.

10. Garcia MG, Faderal S, O’BS, Cortes J, Talpa M, Kantarjian MH. CML: a review and update therapeutic strategies. Am Cancer Society. 2003;98(3):437-57.

11. Qian N, Li X, Wang X, Wu C, Yin L, Zhi X. Tryptase promotes breast cancer angiogenesis through PAR-2 mediated endothelial progenitor cell activation. Oncol Letters. 2018;16(2):1513-20.

12. Marech I, Ammendola M, Léporini C, Patruno R, Luposella M, Zizzo, et al. C-kit receptor and tryptase expressing mast cells correlate with angiogenesis in breast cancer patients. Oncotarget. 2017;9(8):7918.

13. Marech I, Ammendola M, Sacco R, Capriuolo GS, Patruno R, Rubini R, et al. Serum tryptase, mast cells positive to tryptase and microvascular density evaluation in early breast cancer patients: possible translational significance. BMC Cancer. 2014;14(1):534.

14. Xiang M, Gu Y, Lu H, Chen S, Yin L. Mast cell tryptase promotes breast cancer migration and invasion. Oncol Reports. 2010;23(3):615-19.

15. Kankkunen JP, Harvima IT, Naukkarinen A. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer. 1997;72(3):385-8.

16. Ribatti D, Finato N, Crivellato E, Guidolin D, Longo V, Mangieri D, et al. Angiogenesis and mast cells in human breast cancer sentinel lymph nodes with and without micrometastases. Histopathol. 2007;51(6):837-42.

17. Ranieri G, Ammendola M, Patruno R, Celano G, Zito FA, Montemurro S, et al. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009;35(1):115-20.

18. Strouch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, et al. Crosstalk between mast cell and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res. 2010;16(8):2257-65.

19. Guo X, Zhai L, Xue R, Shi J, Zeng Q, Gao C. Mast cell tryptase contributes to pancreatic cancer growth through promoting angiogenesis via activation of angiopoietin-1. Int J Mol Sci. 2016;17(6):834-45.

20. Ammendola M, Gadaleta CD, Frampton AE, Piardi T, Memeo R, Zuccalà V, et al. The density of mast cells e-Kit+and tryptase+ correlates with each other and with angiogenesis in pancreatic cancer patients. Oncotarget. 2017;8(41):463-71.

21. Ammendola M, Sacco R, Donato G, Zuccalà V, Russo E, Luposella M, et al. Mast cell positivity to tryptase correlates with metastatic lymph nodes in gastrointestinal cancer patients treated surgically. Oncol. 2013;85(2):111-6.

22. Malfettone A, Silvestris N, Saponaro C, Ranieri G, Russo A, Caruso S, et al. High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. J Cellular Mol Med. 2013;17(8):1025-37.

23. Ammendola M, Sacco R, Sammarco G, Donato G, Montemurro S, Ruggieri E, et al. Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colorectal cancer patients: possible biological-clinical significance. PLoS ONE. 2014;9(6):e99512.

24. Suzuki S, Ichikawa Y, Nakagawa K, Kumamoto T, Mori R, Matsuyama R, et al. High infiltration of mast cells positive to tryptase predicts worse outcome following resection of colorectal liver metastases. BMC Cancer. 2015;15(1):2-8.

25. Sammarco G, Gadaleta CD, Zuccalà V, Albayrak E, Patruno R, Milella P, et al. Tumor-associated
macrophages and mast cells positive to tryptase are correlated with angiogenesis in surgically-treated gastric cancer patients. Int J Mol Sci. 2018;19(4):1176-90.

26. Ribatti D, Finato N, Crivellato E, Marzullo A, Mangieri D, Nico B, et al. Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. Am J Obstet Gynecol. 2005;193(6):1961-5.

27. Ammendola M, Leporini C, Marech I, Gadaleta CD, Scognamillo G, Sacco R, et al. Targeting mast cells tryptase in tumor microenvironment; a potential antiangiogenetic strategy. BioMed research international. 2014;Article ID 154702.

28. Yoon WH, Jung YJ, Kim TD, Li G, Park BJ, Kim JY, et al. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis. Clin Cancer Res. 2004;10(13):4517-26.

29. Brandi G, Tavolari S, De Rosa F, Di Girolamo S, Agostini V, Barbera MA, et al. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PLoS One. 2012;7(7):e41347.

30. Uchima Y, Sawada T, Nishihara T, Umekawa T, Ohira M, Ishikawa T, et al. Identification of a trypsinogen activity stimulating factor produced by pancreatic cancer cells: its role in tumor invasion and metastasis. Int J Mol Med. 2003;12(6):871-8.

31. Aoyama T, Ino Y, Ozekiet al. Pharmacological studies of FUT-175, Nafamstat Mesylate. I. Inhibition of protease activity in in vitro and in vivo experiments. Japanese J Pharmacol. 1984;35(3):203-27.

32. Tajima H, Ohta T, Elnemr A, Yasui T, Kitagawa H, Fushida S, et al. Enhanced invasiveness of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA. Int J Cancer. 2001;94(5):699-704.

33. Hiroi M, Onda M, Uchida E, Aimoto T. Anti-tumor effect of N-[3, 4-dimethoxycinnamoyl]-anthranilic acid (tranilast) on experimental pancreatic cancer. J Nippon Med School. 2002;69(3):224-34.

34. Subramaniam V, Chakrabarti R, Prud'homme GJ, Jothy S. Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anti-cancer Drugs. 2010;21(4):351-61.

Cite this article as: Mathew A, Naithani M, Sehrawat A, Sundriyal D, Shilpa PV, Nath UK. Tryptase plays a role in solid tumor angiogenesis and cell proliferation. Int J Adv Med 2020;7:1426-32.